NCT03907098
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: FGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with uncontrolled central nervous system metastasis
https://ClinicalTrials.gov/show/NCT03907098